The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease

Young, Jim; Weis, Nina; Hofer, Harald; Irving, William; Weiland, Ola; Giostra, Emiliano; Pascasio, Juan Manuel; Castells, Lluis; Prieto, Martin; Postema, Roelien; Lefevre, Cinira; Evans, David; Bucher, Heiner C; Calleja, Jose Luis

doi:10.1186/s12879-016-2106-x

Scientific article

English

The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease

ContributorsYoung, Jim; Weis, Nina; Hofer, Harald; Irving, William; Weiland, Ola; Giostra, Emiliano; Pascasio, Juan Manuel; Castells, Lluis; Prieto, Martin; Postema, Roelien; Lefevre, Cinira; Evans, David; Bucher, Heiner C; Calleja, Jose Luis

Published inBMC infectious diseases, vol. 17, no. 1, 45

Publication date2017

Abstract

There is limited evidence for the effectiveness of daclatasvir in patients whose hepatitis C threatens their life expectancy. The Named Patient Program in Europe included patients with advanced chronic hepatitis C, a life expectancy of less than 12 months and no other treatment options.

Affiliation entities

Research groups

Citation (ISO format)

YOUNG, Jim et al. The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease. In: BMC infectious diseases, 2017, vol. 17, n° 1, p. 45. doi: 10.1186/s12879-016-2106-x

Article (Published version)

Identifiers

PID : unige:93792
DOI : 10.1186/s12879-016-2106-x
PMID : 28061762

Journal ISSN1471-2334

684views

347downloads

Creation09/03/2017 11:21:00

First validation09/03/2017 11:21:00

Update time15/03/2023 02:37:49

Status update15/03/2023 02:37:48

Last indexation31/10/2024 07:49:30

Archive ouverte UNIGE

The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease

There is limited evidence for the effectiveness of daclatasvir in patients whose hepatitis C threatens their life expectancy. The Named Patient Program in Europe included patients with advanced chronic hepatitis C, a life expectancy of less than 12 months and no other treatment options.

Technical informations